TOPLINE:
Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention.
METHODOLOGY:
- Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known.
- Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition.
- Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition.
TAKEAWAY:
- Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8).
- The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population.
IN PRACTICE:
“Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,” said the lead researcher in a press release.
SOURCE:
This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco.
LIMITATIONS:
This study did not report any specific limitations.
DISCLOSURES:
This study did not report any specific funding or conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.